This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Five Runaway Breakout Stocks to Buy
by David Bartosiak
With the market at all-time highs again, the rich get richer as stocks continue to breakout.
Here's Why Bruker (BRKR) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights: Universal Display, Bruker, Match, j2 and Ciena
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Universal Display, Bruker, Match, j2 and Ciena
5 Top Tech Gainers of 1H19
by Swarup Gupta
The Technology Select Sector SPDR Fund (XLK) is the leading performer among the S&P 500's 11 sectors year to date.
Here's Why You Should Add Bruker (BRKR) to Your Portfolio
by Zacks Equity Research
Investor confidence in Bruker stock (BRKR) is high on substantial potential of MALDI Biotyper.
Teleflex (TFX) Shares Down on Respiratory Care Product Recall
by Zacks Equity Research
Teleflex (TFX) issued a statement saying consumers who own the tampered product should immediately discontinue use and return all affected products.
Bruker (BRKR) Hits a 52-Week High on Solid Growth Drivers
by Zacks Equity Research
Bruker (BRKR) gains from several crucial product launches and acquisitions.
All You Need to Know About Bruker (BRKR) Rating Upgrade to Strong Buy
by Zacks Equity Research
Bruker (BRKR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Methode Electronics (MEI) Q4 Earnings Lag, Sales Up Y/Y
by Zacks Equity Research
Methode Electronics' (MEI) fourth-quarter fiscal 2019 results suffer from weak automotive sales stemming from lower demand for passenger cars.
Bruker (BRKR) Launches the MALDI Biotyper Sirius System
by Zacks Equity Research
The launch is a milestone for Bruker (BRKR) in assay research and clinical studies for fast antibiotic-resistance testing.
IDEXX (IDXX) Gains Traction From Solid CAG, Global Strength
by Zacks Equity Research
IDEXX (IDXX) consistently benefits from strong organic growth, driven by robust sales at the CAG business, fueled by a firm global Catalyst adoption.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Hologic (HOLX) is generating consistent positive results, courtesy of growth initiatives.
Hologic (HOLX) Inks Deal to Acquire SuperSonic Imagine
by Zacks Equity Research
The acquisition of SuperSonic Imagine is in sync with Hologic's (HOLX) strategy to provide wide-ranging screening, interventional and surgical solutions.
QIAGEN Inks Distribution Deal With Mckesson Medical-Surgical
by Zacks Equity Research
The distribution agreement will enable QIAGEN (QGEN) to expand reach in the healthcare market.
Haemonetics on a High Owing to Firm Plasma Arm, Global Growth
by Zacks Equity Research
Continued traction in new business wins and expansion of geographies are lifting Haemonetics' (HAE) performance of late.
Here's Why You Should Invest in Haemonetics (HAE) Stock Now
by Zacks Equity Research
Haemonetics (HAE) benefits from impressive uptick of Hemostasis Management revenues.
NuVasive Grows on Strong Product Adoption Amid Pricing Woe
by Zacks Equity Research
Introduction of multiple products within the Spinal Hardware, balanced revenue growth across key operating segments and robust international sales perk up NuVasive's (NUVA) share price.
Haemonetics' Plant Sell-Off to CLS Plasma to be Strategic Fit
by Zacks Equity Research
This impending divestment remains integral to Haemonetics' (HAE) asset optimization strategy that aims at improving its operational performance and focusing on core competencies.
Teleflex (TFX) Hits New 52-Week High on Solid Growth Drivers
by Zacks Equity Research
Teleflex (TFX) gains from acquisition of NeoTract and Vascular Solutions.
NuVasive Launches Titanium Spine Implant Modulus TLIF-O
by Zacks Equity Research
The launch of Modulus TLIF-O is expected to boost the AMS portfolio of NuVasive (NUVA).
Align (ALGN), Sraumann Cease Talks on iTero Distribution (Revised)
by Zacks Equity Research
The termination of discussion related to Straumann's iTero distribution is a setback for Align Technologies (ALGN), which is currently focusing on expanding its market base for scanners.
LabCorp Diagnostics Shows Robust Growth Amid Price Declines
by Zacks Equity Research
LabCorp's (LH) Diagnostics business sees an organic uptick in terms of both revenues and volumes in spite of further price reductions.
Align (ALGN) Ceases Straumann Distribution Deal, Shares Slip
by Zacks Equity Research
The termination of the Straumann agreement comes as a setback for Align Technologies (ALGN), which is currently focusing on expanding its market base for scanners.
Abbott (ABT) Hits New 52-Week High on Solid Growth Drivers
by Zacks Equity Research
Abbott (ABT) gains from expansion of product portfolio and several regulatory clearances.
Here's Why You Should Invest in Teleflex (TFX) Stock Now
by Zacks Equity Research
Teleflex (TFX) benefits from rising investors' confidence, courtesy of the NeoTract acquisition.